SRR9879275
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.865 |
| 2 | 2ad90ba0-8038-4bad-afa3-d176f63b42f0 | — | — | 0.860 |
| 3 | TCGA-37-3783-01A-01R-1201-07 | — | cohortSQ1 | 0.852 |
| 4 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.851 |
| 5 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.847 |
| 6 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.843 |
| 7 | SRR27320676 | — | — | 0.836 |
| 8 | SRR23036888 | — | — | 0.833 |
| 9 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.832 |
| 10 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.530 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |